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and Shin-Ichi Miyatake4
Abstract
Background: Boron neutron capture therapy (BNCT) is a unique particle radiation therapy based on the nuclear
capture reactions in boron-10. We developed a novel boron-10 containing sodium borocaptate (BSH) derivative,
1-amino-3-fluorocyclobutane-1-carboxylic acid (ACBC)-BSH. ACBC is a tumor selective synthetic amino acid. The
purpose of this study was to assess the biodistribution of ACBC-BSH and its therapeutic efficacy following Boron
Neutron Capture Therapy (BNCT) of the F98 rat glioma.
Methods: We evaluated the biodistribution of three boron-10 compounds, ACBC-BSH, BSH and
boronophenylalanine (BPA), in vitro and in vivo, following intravenous (i.v.) administration and intratumoral (i.t.)
convection-enhanced delivery (CED) in F98 rat glioma bearing rats. For BNCT studies, rats were stratified into five
groups: untreated controls, neutron-irradiation controls, BNCT with BPA/i.v., BNCT with ACBC-BSH/CED, and BNCT
concomitantly using BPA/i.v. and ACBC-BSH/CED.
Results: In vitro, ACBC-BSH attained higher cellular uptake F98 rat glioma cells compared with BSH. In vivo
biodistribution studies following i.v. administration and i.t. CED of ACBC-BSH attained significantly higher boron
concentrations than that of BSH, but much lower than that of BPA. However, following convection enhanced delivery
(CED), ACBC-BSH attained significantly higher tumor concentrations than BPA. The i.t. boron-10 concentrations were
almost equal between the ACBC-BSH/CED group and BPA/i.v. group of rats. The tumor/brain boron-10 concentration
ratio was higher with ACBC-BSH/CED than that of BPA/i.v. group. Based on these data, BNCT studies were carried out in
F98 glioma bearing rats using BPA/i.v. and ACBC-BSH/CED as the delivery agents. The corresponding mean survival times
were 37.4 ± 2.6d and 44.3 ± 8.0d, respectively, and although modest, these differences were statistically significant.
Conclusions: Our findings suggest that further studies are warranted to evaluate ACBC-BSH/CED as a boron delivery agent.
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* Correspondence: neu046@osaka-med.ac.jp
1Department of Neurosurgery, Osaka Medical College, 2-7 Daigakumachi,
Takatuki-shi, Osaka, Japan
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Futamura et al. Radiation Oncology  (2017) 12:26 
DOI 10.1186/s13014-017-0765-4
Background
Various radiation therapy modalities (e.g., stereotactic ra-
diosurgery, intensity-modulated radiation therapy and
particle radiation therapy) have been used in attempts to
improve the prognosis of high-grade gliomas, but the re-
sults have hardly advanced over the past few decades, for
the following two reasons. First, as high-grade gliomas are
highly infiltrative to normal brain parenchyma, the tumor
cells can migrate as far as several centimeters away from
the periphery of the main tumor mass, and thus beam-
limiting irradiation is insufficient to control microscopic
tumor clusters in surrounding normal brain. The second
reason is the low radiosensitivity of glioma cells. It is
almost impossible to eliminate all of the infiltrating tumor
cells within the limits of tolerance for normal brain. Thus,
the selective destruction of tumor cells that have infil-
trated normal brain is an even more difficult challenge
compared with neoplasms at other organs.
At our institution, we have clinically applied boron neu-
tron capture therapy (BNCT) since 2002 as an experimen-
tal adjuvant therapy for patients with recurrent or newly
diagnosed malignant gliomas, and we have achieved
superior outcomes compared with those of the standard
treatment using fractionated photon irradiation [1, 2].
BNCT is a type of particle radiotherapy requiring low-
energy thermal neutrons and non-radioactive boron-10
(10B) compounds that can selectively accumulate in tumor
cells. Following neutron irradiation, fission reaction occurs
neutrons are captured by 10B. This results in high linear
energy transfer (LET) alpha particles and recoiling
lithium-7 nuclei. Since these high-LET particles have lim-
ited path lengths (<10 μm) corresponding to one cell’s
diameter, the lethal effect of these particles is confined to
the 10B-containing cells [3]. Hence, the biological effects
of the 10B (n,α) 7Li capture reaction depends on the
concentration of 10B present in the tumor cells in the
neutron-irradiated field with a concomitant sparing of
normal cell.
Only two 10B drugs, boronophenylalanine (BPA) and
sodium borocaptate (BSH) have been used clinically for
BNCTand these were used separately or together in several
clinical trials of BNCT against high-grade gliomas [1, 2]. At
this time, BPA is a standard therapeutic drug in the clinical
use of BNCT [2]. Since the L-amino acid transport system
is highly expressed in tumor cells compared with normal
cells in most organs including the brain, various boronated
natural amino acids have been intensively tested. At this
point, BPA is considered to be a better 10B delivery agent
than BSH.
In general, inorganic 10B compounds as represented by
BSH have less selectivity for tumors compared with BPA
because of their lack of a cell-specific import system.
Moreover, since BSH can penetrate into the brain only
when the blood-brain barrier (BBB) is disrupted, BSH is
poorly distributed to the tumor-infiltrating areas with an
intact BBB. However, compared with BPA, BSH contains
12 times more 10B per molecule, which is another
significant advantage of BSH over BPA.
ACBC (1-amino-3-fluorocyclobutane-1-carboxylic acid)
is an unnatural amino acid actively taken up by cells with
L-type amino acid transporters [4]. Glioblastoma cells
showed an intense uptake of ACBC [5], and fluoride-
labeled ACBC ([18F]ACBC) was shown to be a useful
tracer in positron emission tomography (PET) to detect
malignant neoplasms [4, 6]. In the present study, we de-
veloped a novel BSH derivative conjugated with 1-amino-
3-fluorocyclobutane-1-carboxylic acid: ACBC-BSH [7],
the chemical structure of which is shown Fig. 1.
The purpose of the present study was 1] to determine
the biodistribution of ACBC-BSH following either i.v. or
i.t CED, and 2] to evaluate and compare it in vivo BNCT




BSH was purchased from Katchem (Prague, Czech
Republic) and dissolved in sterile saline. The ACBC-BSH
was prepared as previously described [7]. BPA (L-isomer)
was kindly supplied by Stella Chemifa (Osaka, Japan) and
was converted to a fructose complex [8].
Cell culture
F98 rat glioma cells have been histologically characterized
as an anaplastic astrocytoma. The F98 cells were a kind gift
from Dr. Rolf Barth (Dept. of Pathology, The Ohio State
University, Columbus, OH) and cultivated in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10%
Fig. 1 The chemical structure of ACBC-BSH
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fetal bovine serum and 10% penicillin/streptomycin/
amphotericin B at 37 °C in a 5% CO2 atm. All of the mate-
rials for cell culture were purchased from Gibco Invitrogen
(Grand Island, NY).
The F98 Rat glioma model
All procedures were performed in accord with the guide for
the care and use of laboratory animals as approved by the
Animal Use Review Board and Ethical Committee of Osaka
Medical College (No. 25092) and Kyoto University
Research Reactor Institute (KUR; Kumatori, Osaka, Japan,
No. 25030). Eight-week-old male Fischer 344 rats weighing
200–230 g were used (Japan SLC, Hamamatsu, Shizuoka).
Each rat was anesthetized with an intraperitoneal injection
of pentobarbital sodium (64.8 mg/kg), and the head was
fixed with a stereotactic frame (Model 900; David Kopf
Instruments, Tujunga, CA). The scalp was incised at the
midline, and a small burr hole was made at the fixed target
(1 mm posterior and 4 mm right lateral to the bregma)
using an electric drill.
A 25-μL Hamilton microsyringe with a 26-ga. needle
(model 1700RN, Hamilton Bonaduz, Bonaduz, Switzerland)
was used for F98 tumor cell transplantation into the rat
brain. The needle was first inserted to 6-mm depth from
the skull and then withdrawn 1 mm to the target in the
brain (5 mm from the skull). F98 cells diluted in 10 μL of
DMEM at a concentration of either 103 cells for the thera-
peutic experiments or 105 cells for the biodistribution
experiments were injected at a rate of 1 μL/min by an auto-
matic infuser pump. The needle was kept in place for
1 min after the infusion and was then slowly withdrawn.
The needle entry port in the burr hole was immediately
sealed with bone wax, and the incised scalp was closed with
a sterilized clip. This F98 brain tumor model rat is resistant
to standard treatment with temozolomide and photon
irradiation [9].
The In vitro uptake of boron drugs in F98 cells
The intracellular 10B concentrations were measured by
means of inductively coupled plasma atomic emission spec-
troscopy (ICP-AES). For the in vitro boron uptake studies,
F98 rat glioma cells were used. First, 105 F98 glioma cells
were seeded into a tissue culture dish (100 × 20 mm;
Becton Dickinson, Franklin Lakes, NJ) with culture
medium (described above) at 37 °C in a 5% CO2 atm. After
incubation for 5 days at 37 °C, the medium was replaced
with culture medium (described above) containing 1 mM
of ACBC-BSH, BSH, or BPA, and the cells were incubated
for an additional 24 h at 37 °C. The medium then was
removed, and the cells werewashed twicewith phosphate-
buffered saline (PBS) and detached with trypsin-
ethylenediamine tetraacetic acid solution. PBS was then
added, and the cells were centrifuged twice and counted
andsedimented.
The cells were then digested for 1 week with 1 N nitric
acid solution (Wako Pure Chemical Industries, Osaka,
Japan), and the boron uptake was determined by induct-
ively coupled plasma atomic emission spectroscopy
(ICP-AES: Hitachi, Tokyo). Pairwise comparisons were
conducted using Student’s t-test. Group differences
resulting in p-values < 0.05 were considered significant.
Implantation of the Alzet osmotic pump for
convection-enhanced delivery
For the convection-enhanced delivery (CED) of the three
10B compounds, the Alzet osmotic pump (model #2001D,
Durect, Cupertino, CA) and the brain infusion kits con-
sisting of a 28-ga., 5-mm-long rigid stainless steel cannula
(Durect) were assembled and filled with 200 μL of the
boron compound solution. After the glioma-bearing rat
was anesthetized, the pump was implanted subcutane-
ously. A needle connecting to the infusion cannula was
inserted via the same burr hole that had been made for
the tumor implantation. The tip of the needle was placed
5 mm below the skull. A total of 1.2 mg 10B/kg rat body
weight (b.w.) of BPA, BSH or ACBC-BSH was delivered at
a constant flow rate of 8 μL/h for 24 h.
The in vivo Biodistribution experiments
After the tumor implantation, when the rats showed signs
suggesting that the tumor growth had become symptomatic
(i.e., weight loss, lethargy, hunching, and ataxia), in vivo
biodistribution studies were initiated. ACBC-BSH, BSH or
BPA was administered intravenously to glioma-bearing rats
at equivalent amounts of 10B adjusted to 12 mg 10B/kg b.w.
ACBC-BSH, was administered i.t. by CED (1.2 mg 10B/kg
b.w.) by means of Alzet osmotic pumps. The biodistribu-
tion of the test agents was determined at 1 and 6 h after
the intravenous (i.v.) administration, and at 1, 6 and 24 h
after the CED using 3 numbers of rats per group. The rats
were euthanized, and the tumor, normal brain, blood, heart,
lung, liver, spleen, kidney, skin and muscle were removed
and weighed. The amount of 10B in each organ was
quantified by ICP-AES. Pairwise comparisons were con-
ducted using Student’s t-test. Group differences resulting in
p-values <0.05 were considered significant.
The intracellular distribution of each boron compound
visualized by immunohistochemical staining
Immunostaining was performed to determine the incorpor-
ation of boron-containing amino acids into F98 cells, as
described by Hattori et al. [7] with some modifications. We
seeded glass coverslips coated with Matrigel (3.5 μg/cm2
protein) with F98 cells (0.8 × 105 cells suspended in 3 mL of
DMEM), and allowed these glass coverslips which be
seeded with F98 cells to settle for 1 h at 37 °C. The medium
was replaced with an equivalent amount of medium con-
taining ACBC-BSH, BSH, or BPA (the final concentration
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was 1 mM in each case), and the cells were cultured for
24 h at 37 °C. Following washing with DMEM, the F98 cells
were fixed with 10% paraformaldehyde in PBS for 10 min
at room temperature and then rinsed with PBS and treated
with 0.05% Triton X-100 for 10 min at room temperature.
Next, the cells were washed with PBS and preincubated in
a humid chamber with 1.0% bovine serum albumin (BSA)/
0.02% NaN3 in PBS at room temperature, followed by incu-
bation with the anti-BSH monoclonal antibody A9H3 [10]
for ACBC-BSH and BSH or the anti-BPA monoclonal anti-
body 2B10 [11] for BPA in PBS containing 1.0% BSA/0.02%
NaN3 (0.2 μg/mL) for 60 min at 32 °C. The cells were rinsed
with PBS and then incubated with Alexa-Fluor® 488Goat
Anti-Mouse IgG in PBS containing BSA/NaN3 (described
above) for 30 min at 32 °C. After being washed with PBS,
the cells were mounted with Permafluor and then
photographed with a microscope (IX-70, Olympus, Tokyo)
equipped with a cooled charge-coupled device camera
(UIC-QE; Molecular Devices, Sunnyvale, CA) controlled by
MetaMorph software (Molecular Devices).
In vivo therapy studies
Studies to evaluate the efficacy of BNCT were performed
with the Kyoto University reactor (KUR), 14 days after the in-
tracerebral implantation of F98 103 glioma cells. Forty glioma
bearing rats were randomly divided into five groups consist-
ing of six animals each with an equal distribution of body
weights. Group 1: untreated controls, Group 2: neutron ir-
radiation only, Group 3: neutron irradiation following BPA/
i.v., Group 4: neutron irradiation following ACBC-BSH/CED,
Group 5: neutron irradiation following the combination of
ACBC-BSH/CED and BPA/i.v. (the combined group).
For the in vivo BNCT studies, ACBC-BSH or BPA was
administered to F98 glioma-bearing rats by means of CED or
i.v., respectively. After the animals were anesthetized with so-
dium pentobarbital, all of their bodies, (except for their head),
were shielded with 6LiF ceramic tiles in order to reduce the
whole-body exposure. At 1 h after the termination of CED or
the i.v. administration of the boron compound, the rats were
irradiated at a reactor power of 1 MW with the Heavy Water
Neutron Irradiation Facility (HWNIF) for 60 min.
The therapeutic effects of BNCT were evaluated by
measuring the rats’ survival times. The mean survival time
(MST), standard deviation (SD), and median survival time
(MeST) were calculated and Kaplan-Meier survival curves
were plotted for all groups. An overall log rank test was
performed to test the equality of the survival curves over
the groups.
Estimation of the physical dose and biologically photon
equivalent dose delivered to F98 glioma-bearing rats in
the BNCT experiments
For the radiation dose analysis of the BNCT experiments,
we estimated the physical dose and the biologically photon
equivalent dose delivered to the rats as described below.
The BNCT dose is the sum total of the physical dose at-
tributed to the 10B(n,α)7Li, 14N(n,p)14C, and 1H(n,n)1H
capture reactions and γ-ray. It is described by using the
following equation:
Physical dose Gyð Þ ¼ DB þ DN þ DH þ Dγ
Here, DB is the physical dose of boron derived from the
equation of 7.43 × 10−14 (Gy cm2/μg 10B/g) × boron concen-
tration (μg 10B/g) × thermal neutron fluence (1/cm2). DN is
the physical dose of nitrogen derived from the equation of
6.78 × 10−14 (Gy cm2/wt.%) × nitrogen concentration (weight
%) × thermal neutron fluence (1/cm2). The numerical values
above were taken from a previous study [12]. The physical
dose of boron and nitrogen is caused by a capture reaction
between the thermal neutrons and each nucleus. The ther-
mal neutron fluence was measured by the radioactivity of
gold foil (0.05 mm thick, 3 mm dia.) that was set at the sur-
face of the rat head. DH is the physical dose of hydrogen that
is caused by the elastic scattering between epithermal or fast
neutrons and the hydrogen nucleus. The simulation using a
general Monte Carlo N-particle transport code [13] was per-
formed in order to correct all dose component caused by
the difference of neutron spectrum between the surface and
tumor site. The simulation was performed with the follow-
ing assumption of the dimension of the rat head. The diam-
eter of the rat head was 25 mm. The tumor with the
diameter of 5 mm was set in the rat head with the 5 mm
distance from the surface. Figure 2 shows the neutron
spectrum at the surface corresponding to the position of
gold foils and tumor site. According to the results of the
simulation, thermal neutron flux at the tumor site was 2%
smaller than at the surface of the rat head. On the other
hand, the epithermal and fast neutron flux at tumor site was
30% smaller than that at the surface of the rat head. There-
fore, in the evaluation of tumor and brain dose, the physical
doses of DB and DN were corrected to be 2% lower than
these doses at the surface. Furthermore, DH was corrected
to be 30% lower than hydrogen dose evaluated by the
surface neutron spectrum which was normalized by the
measured thermal neutron fluence. Finally, the γ-ray dose
was corrected to be 25% larger than the γ-ray dose
measured by a thermoluminescence dosimeter at the surface
of the rat head.
The biologically equivalent total photon dose, hereafter
referred to as the equivalent dose in BNCT was estimated
using the following equation.
Equivalent dose Gy−Eqð Þ ¼ DB  CBEB þ DN
 RBEN þ DH  RBEH
þ Dγ Gyð Þ
CBEB is the compound biological effectiveness (CBE)
for boron compounds, and in the case of BPA, this value
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is 3.8 [14] for tumor tissue and 0.9 [15] for the normal
brain. The relative biological effectiveness (RBE) for ni-
trogen (RBEN) is 3.0. The RBE for hydrogen (RBEH) is
also 3.0 [16]. In the present study, we used 0.9 (this
value was calculated according to a previously described
[15]) as CBE value for the normal brain because 10B
concentration ratio of the normal tissue to the blood (N/
B) of BPA-i.v.-1 h was 3.0/8.5 = 0.35. On the other hand,
in our clinical study [1, 2], we used 1.35 as CBE value
for the normal brain because N/B was 0.63.
The physical dose for ACBC-BSH can be evaluated, but
we were unable to estimate the equivalent dose because the
CBEB for ACBC-BSH is unknown. The nitrogen concentra-
tion was estimated as 2.6% based on International Commis-
sion on Radiation Units and Measurement (ICRU) four
tissue components.
Results
The In vitro uptake of boron drugs in F98 glioma cells
Intracellular 10B concentrations were measured by
means of ICP. The 10B concentrations in F98 glioma
cells at 24 h after their exposure to 1 mM of each 10B
drug are summarized in (Fig. 3a). BPA showed the high-
est concentration (3.27 ± 0.3 μg 10B/107 cells) compared
with ACBC-BSH (1.97 ± 0.2 μg 10B/107 cells; p = 0.0038)
and BSH (0.86 ± 0.1 μg 10B/107 cells; p = 0.0003). ACBC-
BSH also showed a significantly higher B10 concentra-
tion than BSH (p = 0.0014).
In vivo Biodistribution experiments
We measured the 10B concentrations in tumor, normal
brain and blood in F98 glioma-bearing rats after the
administration of BPA, BSH, and ACBC-BSH at the dose
of 12 mg 10B/kg by the i.v. route or 1.2 mg 10B/kg by CED
and the data are summarized in Table 1 and the intratu-
moral (i.t.) 10B localization of each 10B drug are shown in
Fig. 3b and c.
In the i.v. administration experiment (Fig. 3b), BPA
showed significantly higher 10B concentrations in the tu-
mors among the three drugs used, at both 1 h (BPA 19.7
± 1.4 vs. BSH 2.0 ± 1.3 μg 10B/g, p = 0.0001; vs. ACBC-
BSH 2.7 ± 0.5 μg 10B/g, p = 0.000003) and 6 h (BPA 14.4 ±
3.4 vs. BSH 0.5 ± 0.0 μg 10B/g, p = 0.0189; vs. ACBC-BSH
6.0 ± 1.7 μg 10B/g, p = 0.0180) after the injection. ACBC-
BSH was also significantly and highly accumulated in the
tumors compared with BSH at 6 h post-injection (6.0 ±
1.7 vs. 0.5 ± 0.0 μg 10B/g, p = 0.0299).
CED of (Fig. 3c), ACBC-BSH resulted in significantly
higher i.t. 10B concentrations compared with those of
BPA and BSH at 1 h (ACBC-BSH 21.1 ± 3.3 vs. BPA
10.1 ± 4.1 μg 10B/g, p = 0.0225; vs. BSH 12.2 ± 5.6 μg 10B/
g, p = 0.0753), respectively. However, at 6 h (ACBC-BSH
17.8 ± 10.1 vs. BPA 8.9 ± 3.7 μg 10B/g, p = 0.2263; vs.
BSH 15.8 ± 7.7 μg 10B/g, p = 0.8018) this was not the
case. In contrast, BSH did not show any significant differ-
ence compared with BPA at 1 h (BSH 12.2 ± 5.6 vs. BPA
10.1 ± 4.1 μg 10B/g, p = 0.6301) or at 6 h (BSH 15.8 ± 7.7
vs. BPA 8.9 ± 3.7 μg 10B/g, p = 0.2353) post-CED.
The i.t. 10B concentration and the tumor/normal tis-
sues10B ratio: [10B concentration in a tumor] × [Tumor/
Blood 10B ratio] and [10B concentration in a tumor] × [
Tumor/Brain 10B ratio] are as shown in Fig. 3d, e. The i.t.
10B concentration is a main factor correlated with the
therapeutic efficacy of BNCT in the suppression of tumor
Fig. 2 The neutron spectrum at the surface corresponding to the position of gold foils and tumor site
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growth. On the other hand, the tumor/normal tissue ratio
of a 10B concentration is a key factor for the safety of the
normal cells that are included in a neutron-irradiated field.
Since both of these factors are important to ensure the
quality of BNCT, we calculated their product values as in-
dexes reflecting a favorable biodistribution of each 10B
drug.
The i.t. 10B concentration of each drug was similar be-
tween the i.v. (12 mg 10B/kg) and CED (1.2 mg 10B/kg),
but these indexes, i.e., the [10B concentration in a
tumor] × [Tumor/Blood 10B ratio] and [10B concentration
in a tumor] × [Tumor/Brain 10B ratio] were much higher
following CED compared with i.v. administration for all
three drugs (Fig. 3d, e). The boron concentrations in the
liver, spleen, kidney, heart, lung, muscle, and skin follow-
ing CED were < 4.4 μg 10B/g, which were much lower
compared with i.v. administration (data not shown).
Intracellular distribution of each boron compound
visualized by immunochemical staining
Figure 4 showed immunohistochemical staining. The im-
munohistochemical staining showed that the distributions
of ACBC-BSH and BSH were different from that of BPA.
BPA was distributed homogeneously over the cell nucleus
and cytoplasm (Fig. 4d, e, f ). In contrast, ACBC-BSH and
BSH were incorporated into the cell membrane of the F98
cells and aggregated on the fringe of the cell nuclei (Fig. 4g,
h, i, j, k, l).
In vivo therapeutic experiments
We performed therapeutic BNCT experiments using five
groups of rats, and the MST of each group was as follows:
untreated controls, 27.2 ± 2.4 days; neutron-irradiation
controls, 29.8 ± 1.9 days; BNCT with BPA/i.v., 37.4 ±
2.6 days; BNCT with ACBC-BSH/CED, 37.0 ± 5.2 days,
Fig. 3 a Boron concentration of F98 glioma 24 h after incubation in media including 1 mM of each boron compounds. The boron concentrations of
tumor cells were significantly higher in the ACBC-BSH than in the BSH (1.97 ± 0.2 μg B/107 cells and 0.86 ± 0.1 μg B/107 cells). The boron concentrations of
tumor cells were the highest in the BPA. *, P= 0.033; **, P= 0.0014. b Boron concentrations in a tumor in F98 glioma bearing rats, when we administrated
BPA, BSH, and ACBC-BSH at the dose of 12 mg 10B/kg by i.v. ***, P< 0.05. c Boron concentrations in a tumor in F98 glioma bearing rats, when we adminis-
trated BPA, BSH, and ACBC-BSH at the dose of 1.2 mg 10B/kg by CED. ***, P< 0.05. d Product values of the intratumoral 10B concentration and the tumor/
normal tissues 10B ratio; [10B concentration in a tumor] x [Tumor/Blood 10B ratio]. e Product values of the intratumoral 10B concentration and the tumor/nor-
mal tissues 10B ratio; [10B concentration in a tumor] x [Tumor/Brain 10B ratio]
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and BNCT concomitantly using BPA/i.v. and ACBC-BSH/
CED (the combined treatment group), 44.3 ± 8.0 days.
A summary of the boron concentrations and physical
and equivalent doses delivered to F98 glioma-bearing
rats is given in Table 2. The highest physical dose deliv-
ered to the tumor was 3.7 Gy in the ACBC-BSH/CED
group, and the corresponding dose to the normal brain
was 1.1 Gy. The survival data following BNCT are sum-
marized in Table 3, and the Kaplan-Meier survival plots
are shown in Fig. 5.
As shown in Fig. 5, the MST in all BNCT groups (i.e.,
the BNCT with BPA/i.v. group, the BNCT with ACBC-
BSH/CED group, and the combined treatment group)
showed significantly longer survival compared with the
neutron-irradiation control group (p = 0.005, p = 0.002, and
p = 0.0007, respectively). In addition, the combined treat-
ment group showed significantly longer MSTs compared
with the BNCT with BPA/i.v. group (p = 0.0382) and the
highest percent increased lifespan (%ILS) value among all
treated groups (59.2%; Table 3).
Discussion
Extensive studies relating to the use of unnatural amino
acids as boron delivery agents for BNCT have been
reported by Barth, Chandra and Kabalka [17–19]. In the
present study, we designed and synthesized ACBC-BSH,
which is chemically modified BSH with a tumor-avid syn-
thetic unnatural amino acid, ACBC. BSH is a stable poly-
hedral borane that has been shown to be safe in clinical
trials of BNCT, although it does not penetrate into normal
brain with an intact blood-brain barrier (BBB). On the
other hand, intravenously administered BPA penetrates
the BBB by L-amino acid transporters. As reported by
Barth et al although intravenously administered BPA may
penetrate the BBB, it has been shown that intracarotid
(i.c.) administration, combined with BBB disruption, sig-
nificantly enhanced uptake of BPA in F98 glioma bearing
rats [20, 21]. Compared with BPA, BSH contains 12 times
more 10B atoms per molecule, which is a significant ad-
vantage of BSH over BPA. It has been reported that ACBC
could be transported into cells by L-amino acid trans-
porters like phenylalanine and BPA [22, 23], and the PET
using F18-labeled ACBC revealed its tumor selective accu-
mulation [6]. Thus, it may also be useful to visualize and
quantify the distribution of ACBC-BSH in patients with
malignant brain tumors, using PET.
PET is also useful for the detection of brain tumors
[24, 25]. If [18F]ACBC-PET can be used in clinical
Table 1 Summary of Boron biodistribution in F98 glioma bearing rats
Boron concentrations ± SD(μg10B/g) Ratiosb
Agent Route Timea(h) n Blood Brain Tumor T/Bl T/Br
ACBC-BSH CEDc
200μl/24h
1 3 3.3 ± 2.2 1.5 ± 1.3 21.1 ± 3.3 6.4 14.2
6 3 1.3 ± 0.0 0.4 ± 0.3 17.8 ± 10.1 13.7 42.4
24 3 0.5 ± 0.1 0.0 ± 0.0 0.0 ± 0.1 0.1 1.4
i.v.d 1 4 6.3 ± 1.7 0.2 ± 0.0 2.7 ± 0.5 0.4 14.9
6 3 7.0 ± 3.4 0.3 ± 0.1 6.0 ± 1.7 0.9 18.6
BPA CEDe
200μl/24h
1 3 0.5 ± 0.3 0.1 ± 0.1 10.1 ± 4.1 23 125.2
6 2 2.0 ± 0.9 0.7 ± 0.1 8.9 ± 3.7 4.4 13.7
24 3 0.4 ± 0.3 0.0 ± 0.0 0.1 ± 0.2 0.4 7
i.v.f 1 3 8.5 ± 0.3 3.0 ± 0.6 19.7 ± 1.4 2.3 6.7
6 3 4.1 ± 1.3 3.1 ± 1.3 14.4 ± 3.4 3.6 4.7
BSH CEDg
200μl/24h
1 3 0.9 ± 0.7 0.3 ± 0.2 12.2 ± 5.6 13.6 40.7
6 3 1.8 ± 0.5 0.3 ± 0.5 15.8 ± 7.7 8.8 52.7
24 3 1.6 ± 0.3 0.1 ± 0.0 1.4 ± 0.3 0.9 14.0
i.v.h 1 3 10.3 ± 3.3 0.1 ± 0.1 2.0 ± 1.3 0.2 20.0
6 3 2.0 ± 0.3 0.1 ± 0.0 0.5 ± 0.0 0.3 5.0
ACBC α-aminocyclobutane-1-carboxylic acid, CED convection-enhanced delivery, SD standard deviation, BPA p-boronphenylalanine, BSH dodecaboranethiol,
iv intravenous
aTime to euthanize rats after boron compound administration
bT/Bl indicates the tumor to blood ratio and T/Br indicates the tumor to normal brain ratio
cACBC-BSH was administered by long term CED in volume of 200 μl for 24 h at a dose of 1.2 mg10B/kg b.w
dACBC-BSH was administered i.v. at a dose of 12 mg10B/kg b.w
eBPA was administered by long term CED in volume of 200 μl for 24 h at a dose of 1.2 mg10B/kg b.w
fBPA was administered i.v. at a dose of 12 mg10B/kg b.w (= 250 mgBPA/kg b.w)
gBSH was administered by long term CED in volume of 200 μl for 24 h at a dose of 1.2 mg10B/kg b.wl
hBSH was administered i.v. at a dose of 12 mg10B/kg b.w
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practice, it may become a useful modality for deciding
whether to use BNCT with ACBC-BSH. Therefore, in
the present study, we designed and synthesized ACBC-
BSH and elucidated its biodistribution and therapeutic
efficacy in BNCT against malignant glioma. We observed
that it was difficult for ACBC-BSH to pass through the
BBB because of its higher molecular weight. We adopted
CED for the drug administration to solve this problem.
CED is an innovative method for local drug delivery to
brain tumors, by which a pressure gradient, or bulk flow,
Fig. 4 The microdistribution of ACBC-BSH and BPA and BSH in F98 cells. Scale bar =20 μm. a A phase-contrast micrograph of F98 cells that were cultured
in DMEM. b A fluorescence micrograph of F98 cells that were cultured in DMEM stained with the anti-BSH antibody A9H3. c A merged image of A, B. d A
phase-contrast micrograph of F98 cells that were cultured in DMEM containing BPA. e A fluorescence micrograph of F98 cells that were cultured in DMEM
containing BPA stained with the anti-BPA antibody 2B10. f A merged image of D, E. g A phase-contrast micrograph of F98 cells that were cultured in
DMEM containing ACBC-BSH. h A fluorescence micrograph of F98 cells that were cultured in DMEM containing ACBC-BSH stained with the anti-BSH
antibody A9H3. i A merged image of G, H. j A phase-contrast micrograph of F98 cells that were cultured in DMEM containing BSH. k A fluorescence
micrograph of F98 cells that were cultured in DMEM containing BSH stained with the anti-BSH antibody A9H3. l A merged image of J, K
Table 2 Summary of Boron concentrations and Physical doses and Equivalent doses delivered in F98 glioma bearing rats
Boron concentrations ± SD(μg10B/g) Physical doseb (Gy) Equivalent dosec (Gy-Eq)
Agent Route Timea(h) Brain Tumor Brain Tumor Brain Tumor
ACBC-BSH CED 1 1.5 ± 1.3 21.1 ± 3.3 1.1 3.7 - -
BPA iv 1 3.0 ± 0.6 19.7 ± 1.4 1.3 3.5 2.2 11.7
Irradiated Controls - - 0 ± 0 0 ± 0 0.9 0.9 - -
Untreated Controls - - 0 ± 0 0 ± 0 0 0 0 0
DB Boron dose, DN neutron dose, DH hydrogen dose, Dγ gamm-ray dose
CBEB is from CBE(Compound Biological Effectiveness) for DB and, in the case of BPA, this value is 3.8 for the tumor tissue and 0.9 for the normal brain
RBEN is from RBE(Relative Biological Effectiveness) for DN and this value is 3.0
RBEH is from RBE(Relative Biological Effectiveness) for DH and this value is 3.0
aTime to euthanize rats after boron compound administration
bPhysical dose estimates include contributions from gamma photons,10B(n,α)7Li, 14 N(n,p)14C, and 1H(n,n)1H reactions
cEquivalent dose is a value calculated using the DB x CBEB + DN x RBEN + DH x RBEH + Dγ
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is used to drive an infusate through the extracellular
fluid compartment. As demonstrated in animal studies
[26–30], CED not only increased the delivery of both
low- and high-molecular-weight agents, but also im-
proved their therapeutic efficacy. Indeed, we succeeded
in achieving a high accumulation of boron in the tumors
of rats in which ACBC-BSH was administered by CED,
compared with ACBC-BSH administered intravenously.
These results suggest that CED can deliver a variety of
therapeutic agents to tumor-infiltrating areas where the
BBB seems to be intact. In the present study, it was dem-
onstrated that ACBC-BSH accumulated peripherally on
cell nuclei. In vivo, rats that received ACBC-BSH by CED
had higher [10B concentration in a tumor] × [Tumor/
Blood 10B ratio] (1 and 6 h) and [10B concentration in a
tumor] × [Tumor/Brain 10B ratio] (1 and 6 h) values com-
pared with BPA/i.v., although the total amount of 10B of
the ACBC-BSH administered by CED rats (1.2 mg 10B/kg
b.w.) was one-tenth that of BPA/i.v. (12 mg10B/kg b.w.).
This would suggest that ACBC-BSH administered by
CED would be expected to have a greater therapeutic
than BPA administered by i.v.. However, since higher
advantage index includes the score for safety and also
10B concentrations, these were almost equivalent among
the two treatment groups following neutron irradiation,
the superiority of BNCT using ACBC-BSH/CED was
not detected. However, if higher neutron dose was used
to irradiate the tumors, it might be more effective. With
CED of ACBC-BSH the 10B atoms would be expected to
localize at along the periphery of the cell membrane.
The dyshomogeneous subcellular distribution within
cells would reduce its therapeutic effecting. However,
BPA has a more homogeneous distribution within the
cell and it would be advantageous to use both of these
compounds in combination.
Conclusions
Our study demonstrated that the combined administra-
tion of ACBC-BSH/CED and BPA/i.v. resulted a modest
but statistically significant increase in the MST of F98
glioma bearing rats compared with BPA/i.v. suggesting
that further studies are warranted to using ACBC-BSH/
CED as a boron delivery agent.
Table 3 Survival times of F98 glioma bearing rats following i.c.
delivery of BPA and ACBC-BSH by iv or CED
Agent/Route Survival Time %ILSb
Group na Mean ± SD Median Range Median
ACBC-BSH/CED + BPA/iv 6 44.3 ± 8.0 42.0 38–60 59.2
ACBC-BSH/CED 7 37.0 ± 5.2 38.0 31–44 36.0
BPA/iv 5 37.4 ± 2.6 37.0 34–40 37.5
Irradiated Controls 5 29.8 ± 1.9 30.0 27–32 9.6
Untreated Controls 6 27.2 ± 2.4 26.5 25–31 -
ACBC α-aminocyclobutane-1-carboxylic acid, CED convection-enhanced
delivery, SD standard deviation, BPA p-boronphenylalanine,
BSH dodecaboranethiol, iv intravenous
an is the number of animals per group
bPercent increace life span(%ILS) was defined relative to the mean survival
times of untreated controls
Fig. 5 Kaplan-Meier survival curves for F98 glioma cells bearing rats following CED delivery of ACBC-BSH and/or i.v. injection of BPA followed by
BNCT. Survival times in days after implantation have been plotted for untreated animals, irradiated controls, BPA/i.v., ACBC-BSH/CED, ACBC-BSH/
CED + BPA/i.v. groups (n = 3 each)
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barrier; BNCT: Boron neutron capture therapy; BPA: Boronophenylalanine;
BSA: Bovine serum albumin; BSH: Sodium borocaptate; CBE: Compound
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